Met Expression and Survival in Oesophageal Adenocarcinoma
Author Information
Author(s): Tuynman J B, Lagarde S M, ten Kate F J W, Richel D J, van Lanschot J J B
Primary Institution: Academic Medical Centre at the University of Amsterdam
Hypothesis
The study aims to investigate the prognostic significance of Met expression in patients with oesophageal adenocarcinoma.
Conclusion
High Met expression is associated with significantly poorer overall and disease-specific survival in patients with oesophageal adenocarcinoma.
Supporting Evidence
- Patients with high Met expression had a 5-year survival rate of 16% compared to 57% for those with low Met expression.
- High Met expression was linked to a higher likelihood of developing distant metastases and local recurrences.
- Multivariate analysis identified high Met expression as an independent prognostic factor.
Takeaway
If a patient has high levels of a protein called Met in their oesophageal cancer, they are less likely to survive for five years after surgery compared to those with low levels.
Methodology
The study analyzed tumor sections from 145 patients who underwent surgery for oesophageal adenocarcinoma, assessing Met and COX-2 expression through immunohistochemistry.
Limitations
The study's reliance on semiquantitative evaluation of immunohistochemistry may introduce variability.
Participant Demographics
The cohort consisted of 120 men (83%) and 25 women (17%) with a median age of 67 years.
Statistical Information
P-Value
p=0.004
Confidence Interval
95% CI=1.3–4.1
Statistical Significance
p≤0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website